Novo Nordsk makes Wegovy as their injectable weight loss medication and is currently testing an oral version of the drug, Rybelsus. Both contain the same active ingredient, semaglutide, although Rybelsus has a larger amount of semaglutide. Preliminary data indicate that Rybelsus is effective, although probably not as effective as Wegovy. That said, Novo has a serious problem with this drug. Even for Wegovy, they are having a really hard time manufacturing enough of the drug to keep up with demand, and dosing with Rybelsus requires much more drug. The synthesis of Wegovy is quite difficult due to the large size of the drug. The PFE drug (Danuglipron) is much smaller and should have a relatively straight forward synthesis based on the structure. So even though Rybelsus could be viewed as a competitor to Danuglipron, I think that the synthetic/manufacturing issues give PFE a huge advantage. $Pfizer(PFE)$